Tom Daniel has more than 20 years of experience leading and building research and development organizations and leading investments in new companies at the forefront of innovative application of science to healthcare. Recently he served as a Venture Partner at ARCH Venture Partners for five years following a decade as President of Global Research and Early Development at Celgene Corporation. He previously served in senior leadership roles at AmbRx, Amgen and Immunex. Tom was formerly a director at Juno, Epizyme, Sana, Larimar and Vir. He currently serves as board chair at Locanabio, Gate Therapeutics and Trotana, and is director at Vividion, Gossamer Bio, Aspen and Mozart. He chairs the Board of Managers of Life Science Cares-San Diego, is a Trustee of Reed College, is a director at Scripps Research and Chair of the Board of Overseers. He also serves as senior advisor to several private biotechnology companies. A nephrologist and former academic investigator, he was previously C.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University. Dr. Daniel received his M.D. from the University of Texas, Southwestern, trained in molecular genetics at UTSW, and completed his residency in Internal Medicine at Massachusetts General Hospital.
Jean George is a General Partner of Lightstone Ventures. She focuses on biopharmaceutical and medical device investments out of the firm’s Boston office, where she also serves as a General Partner of Advanced Technology Ventures (ATV). Her representative investments include Acceleron Pharma, Calithera Biosciences, Catabasis Pharmaceuticals, Cyteir Therapeutics, Disarm Therapeutics, Flex Pharma, Five Prime Therapeutics, Gemini Therapeutics, Hydra Biosciences, Hypnion (acquired by Eli Lilly), Locanabio, Portola Pharmaceuticals, Proteolix (acquired by Onyx Pharmaceuticals), Tizona Therapeutics, Verastem and Zeltiq Aesthetics.
Jean has been featured on the Forbes Midas List and was previously a member of the Scientific Advisory Board for the Massachusetts Life Sciences Center. She has been in the biopharmaceutical industry for over 20 years, including 10 years with Genzyme Corporation, where she held a variety of operational roles in marketing, product development and business development, including Vice President of Global Sales and Marketing. She also was Vice President and Founder of Genzyme’s Tissue Repair Division.
Jean joined BancBoston Ventures in 1998 to lead its life sciences investments. There, she led investments in Neurometrix, Ironwood Pharmaceuticals, NuGenesis Technologies (acquired by Waters) and Syntonix Pharmaceuticals (acquired by Biogen/Idec). Previously, Jean spent six years working in chemistry and bioresearch and earned an MBA from Simmons College Graduate School of Management.
Rajul is a physician-scientist by background and was most recently leading the Development organization at Kite Pharma, a Gilead company where he oversaw a team of approximately 200 people developing engineered cell therapy products to treat a variety of blood cancers and solid tumors. Rajul joined Kite in 2014 and was instrumental to the company’s growth and success, including the advancement of Yescarta® (axicabtagene ciloleucel) from pre-IND phase through global regulatory approvals.
Previously, Rajul was at Amgen where his last role was Global Development Lead. There he oversaw the development of small molecules and biologics in the oncology and bone health therapeutic areas and was instrumental in advancing the R&D pipeline including regulatory approvals of Xgeva® and Prolia®.
Rajul completed his BA in Chemistry and Biochemistry at Rice University, and MD and Internal Medicine internship and residency at UT Southwestern Medical School, where he was a Howard Hughes Fellow. He completed his post-doctoral training in biophysics at Rockefeller University, and fellowship training at MD Anderson Cancer Center, where he was Chief Fellow.
Rajul has active medical licenses in the states of California and Texas. He was previously a volunteer Attending Physician treating underserved patients at UCLA Harbor Medical Center and is a standing lecturer to graduate students at the UCLA Business of Science Center.
Kevin M. Flanigan, MD, is the Robert F. and Edgar T. Wolfe Foundation Endowed Chair in Neuromuscular Research at Nationwide Children’s Hospital, and Professor of Pediatrics and Neurology at The Ohio State University College of Medicine. Certified by the American Board of Psychiatry and Neurology in both Neurology and Neuromuscular Medicine, Dr. Flanigan is Director of the Center for Gene Therapy in The Research Institute at Nationwide Children's and a leading expert in neuromuscular disorders. He also leads the world-class Neuromuscular Disorders program at Nationwide Children's, which provides coordinated care with pediatric experts from more than a dozen specialties.
Dr. Flanigan earned his medical degree from Rush Medical College and completed his internship at the University of Michigan Health System before completing his Neurology residency and fellowship in Neuromuscular Disorders at the Johns Hopkins Hospital, and an additional post-doctoral laboratory fellowship in Human Molecular Biology and Genetics at the University of Utah.
Nathalie Goemans is a pediatrician and child neurologist, with certification in rehabilitation medicine, affiliated to the KUL University of Leuven, currently emeritus since November 2020. She was a staff member since 1987 at the University Hospitals Leuven, Belgium, as head of clinic within the department of Pediatrics (Child Neurology) and head of the Neuromuscular Reference Centre for Children at the University Hospitals Leuven, and Assistant Professor at the Faculty of Medicine, University of Leuven, Belgium. She is consultant at DVC Heder, Antwerp, Belgium, a rehabilitation center with residential setting for neuromuscular patients.
Research activities involve translational and clinical research in various neuromuscular disorders, the development of new therapies for Duchenne muscular dystrophy and spinal muscular atrophies and the research and development of outcome measures to assess interventions in these diseases.
Dr. McDonald is an internationally recognized pediatric physical medicine & rehabilitation physician who is board-certified in neuromuscular medicine and pediatric rehabilitation medicine. He currently serves as Medical Director of the spina bifida program at Shriners Children's Northern California and is also Professor of Clinical Physical Medicine and Rehabilitation and Professor of Clinical Pediatrics at the University of California Davis School of Medicine. He is also Director of the NIDRR Rehabilitation Research and Training Center in Neuromuscular Disease at the University of California Davis School of Medicine.
Dr. McDonald’s research has focused on the development of novel therapeutics for neuromuscular diseases, and his work has contributed to the development of precision-based therapeutics for Duchenne muscular dystrophy and the first two approved therapies targeting the dystrophin gene abnormalities that cause Duchenne muscular dystrophy. Dr. McDonald's professional affiliations include the Muscular Dystrophy Association, the American Academy of Physical Medicine and Rehabilitation, the American Academy of Cerebral Palsy and Developmental Medicine, the Association of Academic Physiatrists and the American Association of Electrodiagnostic Medicine.
Dr. McDonald earned an AB in Human Biology from Stanford University, an MS in Rehabilitation Medicine from University of Washington and his MD from University of Washington School of Medicine.
Perry Shieh, MD, PhD, is Professor of Neurology at the David Geffen School of Medicine at UCLA. He received his MD and his PhD in Neuroscience from Johns Hopkins University in Baltimore, Maryland. He completed residency training in neurology at Stanford University Hospital and fellowship training in clinical neurophysiology/EMG at Brigham and Women’s Hospital. Dr. Shieh is a member of the American Academy of Neurology and a Fellow of the American Academy of Neuromuscular and Electrodiagnostic Medicine.
Dr. Shieh lectures both nationally and internationally on topics including chronic inflammatory demyelinating polyneuropathy (CIDP), treatments for genetic neuromuscular diseases, the diagnosis of neuromuscular disorders using next-generation sequencing and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy. His research has been published in clinical journals such as Annals of Neurology, Neurology, Nature Genetics and JAMA. Dr. Shieh’s principal clinical interests include Duchene muscular dystrophy (DMD), spinal muscular atrophy, facioscapulohumeral muscular dystrophy (FSHD), myotonic dystrophy, inflammatory myopathy, myasthenia gravis, electromyography and muscle histopathology. He has served as an investigator in numerous clinical trials for neuromuscular conditions.